We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
-3.06%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$77.7B
AUM Growth
-$3.9B
(-4.8%)
Cap. Flow
+$505M
Cap. Flow
% of AUM
0.65%
Top 10 Holdings %
Top 10 Hldgs %
24.09%
Holding
3,066
New
55
Increased
1,481
Reduced
1,461
Closed
51
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$83.5M |
| 2 |
S&P Global
SPGI
|
+$73.5M |
| 3 |
Tesla
TSLA
|
+$55.8M |
| 4 |
Microsoft
MSFT
|
+$45.9M |
| 5 |
Amazon
AMZN
|
+$27.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XLNX
Xilinx Inc
XLNX
|
+$88.8M |
| 2 |
INFO
IHS Markit Ltd. Common Shares
INFO
|
+$74.7M |
| 3 |
CONE
CyrusOne Inc Common Stock
CONE
|
+$31.7M |
| 4 |
Abbott
ABT
|
+$25.5M |
| 5 |
Exelon
EXC
|
+$23.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.74% |
| 2 | Financials | 13.53% |
| 3 | Healthcare | 13.01% |
| 4 | Consumer Discretionary | 11.66% |
| 5 | Industrials | 8.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2576
Acacia Research
ACTG
$470M
| $359K | ﹤0.01% |
79,590
-6,768
| -8% | -$28.4K |
|
2577
Edgewise Therapeutics
EWTX
$4.73B
| $358K | ﹤0.01% |
36,861
+6,350
| +21% | +$81.7K |
|
2578
EyePoint Inc
EYPT
$1.2B
| $358K | ﹤0.01% |
29,463
+7,438
| +34% | +$81.5K |
|
|
GTHX
2579
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $358K | ﹤0.01% |
47,109
-16
| -0% | -$152 |
|
2580
Northrim BanCorp
NRIM
$587M
| $357K | ﹤0.01% |
32,788
-3,252
| -9% | -$36K |
|
2581
OneWater Marine
ONEW
$201M
| $356K | ﹤0.01% |
10,341
+2,669
| +35% | +$129K |
|
|
TBCH
2582
Turtle Beach Corp
TBCH
$277M
| $353K | ﹤0.01% |
16,597
+478
| +3% | +$10K |
|
2583
Kiniksa Pharmaceuticals
KNSA
$5.93B
| $352K | ﹤0.01% |
35,394
+737
| +2% | +$7.81K |
|
|
KRON
2584
DELISTED
Kronos Bio
KRON
| $352K | ﹤0.01% |
48,728
-2,657
| -5% | -$22.7K |
|
2585
908 Devices
MASS
$364M
| $352K | ﹤0.01% |
18,530
+6,185
| +50% | +$106K |
|
2586
MediaAlpha
MAX
$821M
| $352K | ﹤0.01% |
21,299
+2,205
| +12% | +$30.8K |
|
|
ESMT
2587
DELISTED
EngageSmart, Inc.
ESMT
| $352K | ﹤0.01% |
16,531
+5,366
| +48% | +$111K |
|
2588
EverCommerce
EVCM
$1.93B
| $350K | ﹤0.01% |
26,533
+15,025
| +131% | +$186K |
|
|
MLNK
2589
DELISTED
MeridianLink
MLNK
| $350K | ﹤0.01% |
+19,364
| New | +$361K |
|
2590
Identive
INVE
$61.9M
| $347K | ﹤0.01% |
21,447
+5,057
| +31% | +$97.1K |
|
|
MRNS
2591
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $347K | ﹤0.01% |
37,114
+1,257
| +4% | +$12.5K |
|
|
ITIC
2592
Investors Title Co
ITIC
$547M
| $346K | ﹤0.01% |
1,704
-136
| -7% | -$27.1K |
|
2593
Foghorn Therapeutics
FHTX
$360M
| $345K | ﹤0.01% |
22,676
+3,223
| +17% | +$44.2K |
|
2594
Standard BioTools
LAB
$314M
| $345K | ﹤0.01% |
96,009
-8,203
| -8% | -$28.3K |
|
|
IMGO
2595
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $345K | ﹤0.01% |
+17,881
| New | +$371K |
|
|
MMAT
2596
DELISTED
Meta Materials Inc. Common Stock
MMAT
| $342K | ﹤0.01% |
2,051
-345
| -14% | -$64.2K |
|
2597
Monte Rosa Therapeutics
GLUE
$1.35B
| $339K | ﹤0.01% |
+24,192
| New | +$336K |
|
2598
Atlanta Braves Holdings Series A
BATRA
$3.43B
| $337K | ﹤0.01% |
11,715
-1,444
| -11% | -$39K |
|
2599
Sweetgreen
SG
$642M
| $337K | ﹤0.01% |
+10,521
| New | +$306K |
|
2600
Cullinan Oncology
CGEM
$1.14B
| $336K | ﹤0.01% |
32,045
+1,445
| +5% | +$19.5K |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2022 Portfolio in Review
As of Q1 2022, RhumbLine Advisers held 3,066 positions worth $77.7B, down 4.8% from $81.6B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Trading was light in Q1 2022: portfolio turnover was 3.5%. RhumbLine Advisers opened 55 new positions and exited 51, leaving the 3,066-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 26% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q1 2022 buy was Constellation Energy: 528,261 shares worth $29.7M.
- RhumbLine Advisers added most to Advanced Micro Devices in Q1 2022, an estimated $83.5M increase.
- RhumbLine Advisers's biggest Q1 2022 reduction was Abbott, cutting an estimated $25.5M.
- RhumbLine Advisers fully exited Xilinx Inc in Q1 2022, selling an estimated $88.8M.
- RhumbLine Advisers's ten largest holdings make up 24% of its $77.7B portfolio in Q1 2022.
- RhumbLine Advisers opened 55 new positions and closed 51 in Q1 2022.
- RhumbLine Advisers's portfolio value fell 4.8% quarter-over-quarter to $77.7B.
Based on RhumbLine Advisers's 13F filing for Q1 2022, filed 12 May 2022.